E253 - Executing A Product Pivot With Vir Bio's Mark Eisner, MD

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Bio, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and his own transition from healthcare provider to clinical research. 

This episode is brought to you by Avantor. For more information, visit avantorsciences.com

Access this and hundreds of e...